



## ALPHAGAN<sup>®</sup> P Fact Sheet

### About ALPHAGAN<sup>®</sup> P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%

The No. 1 branded adjunct to a lipid,<sup>1</sup> the ALPHAGAN<sup>®</sup> ophthalmic solution franchise has been a leading group of therapies for reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension safely and effectively for more than five years. ALPHAGAN<sup>®</sup> P 0.1%, approved by the U.S. Food and Drug Administration (FDA) in 2005, is an improved formulation of the original ALPHAGAN<sup>®</sup> 0.2% and ALPHAGAN<sup>®</sup> P 0.15%.

### How ALPHAGAN<sup>®</sup> P Works

ALPHAGAN<sup>®</sup> reduces production of aqueous humor, the fluid in the eye that fills the space between the back surface of the cornea and the front surface of the vitreous humor, and enhances aqueous humor drainage via the uveoscleral pathway.<sup>2</sup> The recommended dosage is one drop of ALPHAGAN<sup>®</sup> P 0.1% in the affected eye(s) three times daily, approximately eight hours apart.

### ALPHAGAN<sup>®</sup> P Key Benefits

- Many glaucoma patients have co-existing systemic disorders.<sup>3</sup> ALPHAGAN<sup>®</sup> P 0.1% offers a favorable safety profile with no cardiopulmonary contraindications and no label warning or precautions regarding patients with diabetes, sexual dysfunction and obstructive pulmonary disease. ALPHAGAN<sup>®</sup> P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. Patients prescribed IOP-lowering medication should be routinely monitored for IOP.
- With ALPHAGAN<sup>®</sup> P 0.1%, the drug concentration from the original product, ALPHAGAN<sup>®</sup> 0.2% ophthalmic solution has been decreased by 50 percent without sacrificing efficacy.
- ALPHAGAN<sup>®</sup> P 0.1% and 0.15% solutions contain PURITE<sup>®</sup>, a gentle-to-the-eye preservative used in other Allergan products.



### ALPHAGAN<sup>®</sup> P Efficacy

Results from a 12-month clinical trial show that IOP reductions with ALPHAGAN<sup>®</sup> P 0.15% were clinically equivalent to original ALPHAGAN<sup>®</sup> 0.2%. The difference in mean IOP was less than 1 mm Hg at all follow-up time points over 12 months.<sup>4</sup> ALPHAGAN<sup>®</sup> P 0.1% contains the lowest effective concentration of brimonidine and is preserved with PURITE<sup>®</sup> preservative to enhance ocular tolerability. An additional study demonstrated that ALPHAGAN<sup>®</sup> P 0.1% is as effective in reducing IOP as the original brimonidine 0.2% solution preserved with benzalkonium chloride.<sup>5</sup>



Please see important safety information on next page.

- more -

## About Glaucoma

Glaucoma, a group of eye diseases characterized by damage to the optic nerve, is the leading cause of preventable blindness in the United States.<sup>6</sup> It is estimated that three million Americans have glaucoma, but only half of those know they have it.<sup>7</sup> The total number of glaucoma cases worldwide is estimated to be 65 million.<sup>7</sup> One of the risk factors of glaucoma is elevated IOP, or pressure inside the eye. A healthy eye produces fluids, called aqueous humor, at the same rate fluids are drained. If the aqueous humor is not removed rapidly enough or the eye fills too rapidly, pressure builds up in the eye, which can result in glaucoma. This high pressure distorts the shape and damages the optic nerve. Maintaining healthy IOP levels may slow the progression of the disease and help prevent glaucomatous loss of vision.

###

**Contact:**     **Heather Katt**  
Allergan, Inc.  
(714) 246-6224  
[katt\\_heather@allergan.com](mailto:katt_heather@allergan.com)

## Important ALPHAGAN<sup>®</sup> P Safety Information

ALPHAGAN<sup>®</sup> P 0.1% and 0.15% is contraindicated in patients receiving monoamine oxidase inhibitor therapy. Although ALPHAGAN<sup>®</sup> P 0.1% and 0.15% ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease. Adverse events associated with ALPHAGAN<sup>®</sup> P 0.1% to 0.2% occurring in approximately 10 to 20 percent of patients included allergic conjunctivitis, conjunctival hyperemia and eye pruritus. Please refer to full prescribing information. For more information about ALPHAGAN<sup>®</sup> P ophthalmic solution, please refer to the full [prescribing information](#) and the product Web site at [www.alphaganp.com](http://www.alphaganp.com).

<sup>®</sup> Marks owned by Allergan, Inc.

---

<sup>1</sup> Verispan LLC. *Physician Drug and Diagnosis Audit*. Yardley, Pa: Verispan LLC; 2006.

<sup>2</sup> Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. *Arch Ophthalmol*. 1995;113(12):1514-1517.

<sup>3</sup> Gottfredsdottir MS, Allingham RR, Shieds MB. Physicians' guide to interactions between glaucoma and systemic medications. *J Glaucoma*. 1997; 6(6):377-383.

<sup>4</sup> Katz L. Twelve-Month Evaluation of Brimonidine-Purite Versus Brimonidine in Patients with Glaucoma or Ocular Hypertension. *J Glaucoma*. 11(2) 119-126. 2002.

<sup>5</sup> Cantor, L. Brimonidine in the treatment of glaucoma and ocular hypertension. *Therapeutics & Clinical Risk Mgmt*. Print ISSN: 1176-6336; Volume: 2 | Issue: 4; 2006.

<sup>6</sup> The Glaucoma Foundation. "TGF Urges Eye Exams to Detect the Disease Early." January 8, 2006. Available at: [http://www.glaucomafoundation.org/news\\_story.php?i=38](http://www.glaucomafoundation.org/news_story.php?i=38). Accessed April 19, 2007.

<sup>7</sup> Glaucoma Research Foundation. "Glaucoma Facts and Stats." Available at: [http://www.glaucoma.org/learn/glaucoma\\_facts.html](http://www.glaucoma.org/learn/glaucoma_facts.html). Accessed: July 31, 2007.